An impact on prognosis emerged when we focused on genetically undefined patients, that means with intermediate-risk or lack of growth karyotype, and triple-negative for NPM1, FLT3-ITD and CEBPA (TN-AML). This evidence concerns the gene NPM1 and acute myeloid leukemia.